⚠️
Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
Respiratory tract congestion
11,199 total reports14.6% serious outcomes
Share
11,199
Total Reports
232
Deaths
1,407
Hospitalizations
14.6
Severity Rate
% serious outcomes
About Respiratory tract congestion Reports
Respiratory tract congestion has been reported 11,199 times in VAERS from 1990 to 2026.
Of these reports, 232 were associated with death (2.07%) and 1,407 involved hospitalization.
The overall serious outcome rate (death or hospitalization) for reports mentioning Respiratory tract congestion is 14.6%.
Understanding Respiratory tract congestion in VAERS
•Temporal association only: These reports show Respiratory tract congestion occurred after vaccination, not necessarily because of vaccination.
•Background rates matter: Many symptoms occur naturally at baseline rates in the population, unrelated to vaccination.
•Reporting variability: Medical terminology may be used differently by various healthcare providers and over time.
•Investigation needed: High-frequency reports may trigger further epidemiological studies to determine causation.
What This Data Shows
Most Associated Vaccines: The vaccines most frequently mentioned in reports with Respiratory tract congestion. This may reflect usage patterns, not causation.
Severity Patterns: The percentage of reports that involve serious outcomes can help prioritize safety investigations.
Reporting Trends: Changes in reporting frequency over time may reflect increased awareness, media attention, or actual safety signals.
Most Associated Vaccines
1. COVID198,858
2. COVID19-21,595
3. FLU3555
4. FLUX395
5. FLU4390
6. VARZOS236
7. UNK207
8. PNC13198
9. MMR164
10. PPV147
Quick Facts
Reports:11,199
Deaths:232
Hospitalizations:1,407
Mortality Rate:2.07%
Severity Rate:14.6%
Related Analysis
Explore Further
Data Source
This data comes from the Vaccine Adverse Event Reporting System (VAERS), jointly managed by CDC and FDA.